As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

Jacob Lalezari of CytoDyn shares insights about CCR5-targeting therapy for cancer, including triple negative breast cancer and colorectal cancer.

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S. commercialization of Rexulti to oversee the planned launch of a GLP-1 receptor antagonist ...

BERLIN — Lusvertikimab, a first-in-class interleukin 7 (IL-7) receptor antagonist, demonstrated clinical and endoscopic efficacy in patients with moderate to severe ulcerative colitis (UC) in the ...

Please provide your email address to receive an email when new articles are posted on . The addition of leukotriene receptor antagonists to antihistamines improved urticaria symptoms. The combination ...